Pfizer (PFE) recently announced positive topline results from the Phase 3 EV-303 clinical trial, showcasing promising outcomes for PADCEV in treating muscle-invasive bladder cancer. Over the last ...

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the ...

Aug 5 - Pfizer (NYSE:PFE) heads into its Q2 earnings release amid growing investor caution. Analysts expect revenue around ...

Chasing a 100 times return might not be a great idea. But there are lessons to be taken from past winners of this magnitude.

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

As Wall Street embarks on the first full week of August, the earnings wave continues with another stacked week of reports ...

U.S. stock futures are edging higher early Tuesday as markets rebound on expectations of a September rate cut. On Friday, the Bureau of Labor ...

Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer's strong EPS surprise streak and positive earnings revisions are encouraging, but patent cliff risks remain a major ...